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Abstract
Change of the thickness from skin surface to masseter 
muscle after botulinum toxin injection 
into human masseter muscle
Gunwoo Park
Department of Dental Science
The Graduate School, Yonsei University
(Directed by Professor Seong Taek Kim, D.D.S., Ph.D.)
Botulinum toxin is widely used to treat masseter muscle hypertrophy. It affects the end 
of neuron to decrease acetylcholine secretion, causing muscle atrophy which leads to cure. 
Change of muscle thickness has been reported in many studies. However, there has been 
no report about change in the thickness from skin surface to masseter muscle. In this 
study, we aim to measure not only change of muscle thickness but also the change of
thickness from skin surface to masseter muscle by using ultrasonography.
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A total of 17 volunteers were enrolled in this study. 10 patients were assigned to an 
experimental group (injected 25 U of botulinum toxin on both masseter muscle) and 7 to 
a control group (injected normal saline). Thickness was measured before injection and 4
weeks, 8 weeks, 12 weeks after the injection each at rest and during maximum clenching.
Result showed that thickness from skin surface to masseter muscle did not show 
significant difference by time at rest (p = 0.063) and maximum contraction state (p =
0.392). There was also no significant difference between experimental group and control 
group at rest (p = 0.392) and during maximum clenching (p = 0.259). Muscle thickness of 
experimental group showed a significant difference by time. In conclusion, botulinum 
toxin injection only affects change in muscle thickness and does not affect thickness from 
skin surface to masseter muscle.
Keywords: Botulinum toxin (BoNT), masseter, ultrasonography
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I. INTRODUCTION
Masseter muscle hypertrophy is an abnormal hypertrophy of unilateral or bilateral 
masseter. It has been first reported by Legg and has been reported several times since, but 
there is still a controversy over its etiology (Legg, 1880). In the past, surgical methods 
such as masseter resection have been chosen as a treatment. However, reversible and 
preservative treatment methods have been required due to post-operative complications 
and repulsion of patients.
2Botulinum toxin (BoNT) is a substance made by clostridium botulinum, causing 
temporary chemodenervation by suppressing acetylcholine secretion in neuromuscular 
junctions (Burgen et al., 1949; Wheeler and Smith, 2013). As a result, it causes muscle 
paresis and atrophy in striated muscles. BoNT is being used not only in FDA approved 
fields such as bladder dysfunction, chronic migraine, upper limb spasticity, cervical 
dystonia, primary axillary hyperhidrosis, blepharospasm, and strabismus, but also in 
various neuromuscular disorders as an off-label use (Bigalke, 2013).
Using BoNT to treat masseter muscle hypertrophy was first introduced in 1994 in a 
field of plastic surgery (Moore and Wood, 1994). Using BoNT in treating masseter 
muscle hypertrophy patients is being considered as a safer, simpler and noninvasive 
method than surgical treatment and is widely used in clinic.
Studies that were made in the past using BoNT in masseter muscle hypertrophy 
measured its effect by photography (Castro et al., 2005), computed tomography (CT)
(Chang et al., 2011; Kim et al., 2003; Kim et al., 2007; No et al., 2015; Park et al., 2003; 
Yu et al., 2007), magnetic resonance imaging (MRI) (Raadsheer et al., 1994; Rijsdijk et 
al., 1998), three-dimensional (3D) image (Cha et al., 2013; Lee et al., 2015; Shim et al., 
2010), and ultrasonography (Choe et al., 2005; Kim et al., 2010; To et al., 2001; Wei et
al., 2015). These studies report that BoNT injection causes masseter muscle atrophy 
which decreases lower facial volume.
BoNT is generally known to only affect muscle. However, assumptions that it could 
have an effect on tissues other than muscle are being brought up. Tsai et al. reported 
decrease of cortical thickness, trabecular thickness and bone mineral content in mandible 
3of adult rats after BoNT injection on unilateral masseter muscle (Tsai et al., 2010). 
Rafferty et al. reported condyle bone loss in adult rabbits after BoNT injection on 
unilateral masseter muscle (Rafferty et al., 2012). Kun-Darbois et al. reported alveolar 
bone and condylar bone loss in adult rats after BoNT injection on unilateral masseter and 
temporalis muscle (Kun-Darbois et al., 2015). 
BoNT injection may cause change in thickness from skin surface to masseter muscle
(S-M) by diffusing effect to adjacent tissue or by body weight loss caused by masticatory 
disturbance due to decreased chewing force. However, change in S-M thickness after 
BoNT injection has not been studied until now. 
The purpose of this study is to measure S-M and masster muscle thickness after BoNT 
injection to see the difference and find out if change in S-M thickness is occur.
4II. SUBJECTS AND METHODS
1. Subjects
The study population consisted of 17 volunteers who requested treatment of masseter 
hypertrophy in Seoul, Korea. The volunteers were randomly divided into 2 groups. Ten 
volunteers (3 men and 7 women) aged 21 to 40 years (mean age, 29.8 years) received a 
single BoNT injection (Experimental group), whereas the remaining 7 volunteers (2 men 
and 5 women) aged 27 to 40 years (mean age, 30.9 years) received saline injections 
(Control group). The exclusion criteria were pregnancy, a history of any serious medical 
illnesses including drug allergy and who have had BoNT injection, orthodontic treatment, 
or plastic surgery within 1 year. During the experimentation several drugs that can affect 
muscles were prohibited including muscle relaxants, benzodiazepine and anticholinergic 
drugs.
52. Methods
2.1. Injection of botulinum toxin type A
BoNT (Meditoxin®; Medytox, Ochang, Korea) was supplied as a freeze-dried powder 
and reconstituted at a concentration of 50 U/mL (100 U in 2 mL of sterile saline) and used 
immediately. A volume of 25 U of BoNT was injected into the masseter muscle bilaterally 
using a 1-mL syringe with a 29-G ½-inch-long needle. Injections were performed at 2 
points, 1 cm apart at the center of the middle one third of the masseter muscle [Figure 1].
Figure 1. Red point shows the BoNT injection site (Hu et al., 2010).
62.2. Ultrasonography procedure
All scans were performed using a E-cube9 diagnostic ultrasound (Alpinion, Seoul, 
Korea) using a frequency 3.0–12.0 MHz broadband linear transducer (L3-12H, Seoul, 
Korea). The characteristics of the preset were: frequency 12.0 MHz; dynamic range 70; 
gain setting 50; frame rate 59; and depth 3.0. The transmission gel was applied to the 
probe before the imaging procedure. 
The masseter muscle was scanned bilaterally on Cheilion-Obi (Otobasion inferius) line 
which is horizontal reference [Figure 2]. During imaging, the transducer was held 
perpendicular to the surface of the skin and care was taken to avoid excessive pressure. 
To be perpendicular to the ramus the transducer was tilted until the ramus was depicted 
on the screen as a sharp white line. The thickness was defined as the largest distance 
between ramus and masseter muscle surface, perpendicular to the underlying ramus.
The imaging and measurements were performed with the subjects in an upright 
position under two different conditions [Figure 3]:
(A) When teeth are not contact with muscle in a relaxed position: physiologic resting 
position
(B) During maximum clenching with the masseter muscle contracted 
The measurements were made directly from the image at the time of scanning. The 
thickness of S-M and masseter muscle was measured 4 times using an ultrasonography; 
before the injection, 4, 8, and 12 weeks after the injection. 
7Figure 2. Horizontal reference of ultrasonography: Cheilion (a cephalometric point located at the 
corner of the mouth) - Obi (a cephalometric point of attachment of the ear lobe to the cheek)
Figure 3. (A) Ultrasound image at rest, (B) Ultrasound image during maximum clenching. The 
orange color arrow indicate the thickness of the S-M and masseter muscle (M).
82.3. Statistical analysis
Data were analyzed using SPSS 20 software (SPSS, Inc., Chicago, IL, USA). 
Measurement of thickness of S-M and muscle was made both rest and maximum 
clenching state by time, calculating mean value and standard deviation. To evaluate 
statistical significance of change in thickness by time and group, we used two-way 
repeated measures Analysis of variance (ANOVA). Mauchly's sphericity test was used to 
verify the independent variable. When p-value of Mauchly's sphericity test was lower 
than 0.05, Greenhouse-Geisser (epsilon < 0.75) and Huynh-Feldt (epsilon > 0.75) was 
used to modify degrees of freedom. P-value was considered statistically significant when 
it is less than 0.05. Values are presented as mean ± standard deviation.
9III. RESULTS
Table 1 shows that change of S-M and masseter muscle thickness at rest. There was no 
significant difference of S-M thickness by time (p = 0.063) or group (p = 0.392). No 
significant interaction between time and group was seen (p = 0.823) in S-M thickness. 
Significant interaction between time and group was seen in masseter muscle thickness (p
= 0.024), and large amount of decrease in thickness was seen in experimental group 
compared to control group [Figure 4].
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Table 1. Mean changes in the thickness of S-M and masseter muscle at resta. 
Pre-injection 4 weeks 8 weeks 12 weeks Time Group Time*Group
m ± σ m ± σ m ± σ m ± σ p p p
S-Mb
Exp 5.79 ± 0.97 5.55 ± 1.12 5.73 ± 1.10 5.91 ± 1.43
0.063 0.392 0.823
Con 5.41 ± 0.68 5.20 ± 0.80 5.15 ± 0.62 5.55 ± 0.92
Mc
Exp 14.19 ± 2.13 12.51 ± 3.23 11.76 ± 2.67 11.27 ± 2.85
0.001* 0.121 0.024*
Con 14.84 ± 2.93 14.60 ± 2.75 14.28 ± 2.31 14.30 ± 2.50
a Main effects and interactions were tested by two-way repeated measure ANOVA
b No significant interaction and main effect of time and group.
c Significant interaction of time and group (with Greenhouse-Geisser correction, epsilon = 0.650, F = 4.279, p = 0.024) and significant main 
effect of time (with Greenhouse-Geisser correction, epsilon = 0.650, F = 9.677, p = 0.001). No significant main effect of group.
* p < 0.05
S-M: thickness from skin surface to masseter muscle (mm), M: thickness of masseter muscle (mm), Exp: experimental group, Con: control 
group, m: mean, σ: standard deviation
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Figure 4. Mean changes in the thickness of S-M and masseter muscle at rest. Exp: experimental 
group, Con: control group
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Exp S-M Con S-M Exp muscle Con muscle
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Table 2 shows that change of S-M and masseter muscle thickness during maximum 
clenching. There was no significant difference of S-M thickness by time (p = 0.166) or 
group (p = 0.259). No significant interaction between time and group was seen (p = 0.115)
in S-M thickness. Significant interaction between time and group was seen in masseter 
muscle thickness (p = 0.025), and large amount of decrease in thickness was seen in 
experimental group compared to control group [Figure 5].
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Table 2. Mean changes in the thickness of S-M and masseter muscle during maximum clenchinga.
Pre-injection 4 weeks 8 weeks 12 weeks Time Group Time*Group
m ± σ m ± σ m ± σ m ± σ p p p
S-Mb
Exp 4.84 ± 0.92 5.42 ± 1.19 5.14 ± 1.12 5.30 ± 1.24
0.166 0.259 0.115
Con 4.75 ± 0.66 4.69 ± 0.70 4.45 ± 0.58 4.70 ± 0.86
Mc
Exp 16.58 ± 2.17 14.04 ± 3.48 13.72 ± 2.87 13.24 ± 2.97
0.002* 0.082 0.025*
Con 17.01 ± 2.25 16.56 ± 2.09 14.46 ± 2.13 16.47 ± 1.84
a Main effects and interactions were tested by two-way repeated measure ANOVA
b No significant interaction and main effect of time and group.
c Significant interaction of time and group (with Greenhouse-Geisser correction, epsilon = 0.484, F = 4.956, p = 0.025) and significant main 
effect of time (with Greenhouse-Geisser correction, epsilon = 0.650, F = 9.907, p = 0.002). No significant main effect of group.
* p < 0.05
S-M: thickness from skin surface to masseter muscle (mm), M: thickness of masseter muscle (mm), Exp: experimental group, Con: control 
group, m: mean, σ: standard deviation
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Figure 5. Mean changes in the thickness of S-M and masseter muscle during maximum clenching. 
Exp: experimental group, Con: control group
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IV. DISCUSSION
Square-faced is caused complexly by protrusion of mandibular angle and hypertrophy 
of masseter muscle (Baek et al., 1994). Koreans have wide mandible because they are 
classified as a Mongolian race. Moreover, traditional Korean food is mostly rough and 
hard, promoting muscular development of masseter muscle. In Asian women, standard of 
beauty is related with slim face and soft looking feature, making square-faced patients as 
problem that needs to be treated (Ahn et al., 2004; Yuan et al., 2013).
Masseter muscle hypertrophy is a common cause of square-faced patients. It is 
occurred mostly by parafunction such as bruxism or clenching and also by dietary habit. 
Various treatments were introduced to reduce masseter muscle volume. It can be treated 
surgically but side effects such as post-operative pain, delayed healing time, bleeding, and 
nerve injury can be caused (Huang et al., 2003).
BoNT is one of the neurotoxin protein (A, B, C1, C2, D, E, F and G) produced by 
Clostridium botulinum, which is an anaerobe that causes food poisoning. Clostridium 
botulinum was first extracted in 1897 by Van Ermengen from a dead body and salted pork, 
and BoNT was separated and refined in 1946 by Edward J. Schantz. In 1949, Burgen et al. 
reported that BoNT suppressed contraction of muscle by depressing acetylcholine 
secretion at the end of cholinergic nerve (Burgen et al., 1949; Jankovic and Brin, 1997). 
By this function, when injected into masseter, reversible decrease in contraction force and 
volume of muscle has been observed. In the 1990s, BoNT started to replace surgical 
methods in many clinics (Jankovic and Brin, 1991).
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In previous studies, BoNT injection was proven to be effective in decreasing size of 
masseter muscle. In these studies, photography, CT, MRI, 3D image, ultrasonography were 
used to detect changes (Castro et al., 2005; Cha et al., 2013; Chang et al., 2011; Choe et al., 
2005; Kim et al., 2003; Kim et al., 2007; Kim et al., 2010; Lee et al., 2015; No et al., 2015; 
Park et al., 2003; Raadsheer et al., 1994; Rijsdijk et al., 1998; Shim et al., 2010; To et al., 
2001; Wei et al., 2015; Yu et al., 2007). Among them, CT, MRI and ultrasonography can be 
used to measure S-M thickness. Repeated measurement by taking CT can cause problem by 
increase in patient’s radiation exposure rate. MRI does not have such problems but it is 
expensive and difficult to acquire subdivided image, which makes it hard to expect exact 
value. In clinic, ultrasonography is favorable for its fast, easy, and harmless feature.
Published paper that measures thickness of masseter with ultrasonography has different 
measuring reference. Volk et al. placed the probe transversely at middle of zygomatic 
bone and mandibular angle (Volk et al., 2014). Other studies just measured at maximum 
thickness or had no indication about reference point.
Emshoff et al. reported that masseter muscle seems to be thickest in the middle area 
when divided into 5 from origin to insertion (Emshoff et al., 2003). Raadsheer et al. 
reported that measurement value of masseter using MRI and ultrasonography is highly 
related, and it was most highly related when measured at the middle of masseter
(Raadsheer et al., 1994). Suh et al. reported that maximal thick point of masseter muscle 
from the mandibular angle in Koreans was 27.77mm in male and 25.79mm in female.
Maximal thick point between mandibular angle and zygomatic arch was located in the
area of 53% and 59% from mandibular angle each in male and female (Suh et al., 2011).
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Therefore, in this study, we tried to minimize the errors from change of reference point 
while repeating the measurement of maximum thickness of S-M and masseter muscle by
setting Cheilion-Obi line as a reference.
BoNT injection can directly affect adjacent tissue other than masseter muscle by drug 
diffusion or indirectly affect S-M thickness by weakening chewing force. S-M layer 
consists of epidermis, dermis, subcutaneous tissue. Subcutaneous tissue is mainly 
composed of fat tissue, which has a very close relationship with weight difference
(Deurenberg et al., 1998). If BoNT injection decreases food intake due to weakness of 
masticatory function, weight loss and body fat decrease can occur. This can lead to
decrease of subcutaneous tissue thickness. However, in this study, we did not measure 
body weight and body fat difference, which should be supplemented on following studies.
BoNT diffusion potency was studied by several authors. Studies in experimental 
animals have shown that 5 – 10U of BoNT has biologic activity 4.5 cm from the injection 
site within the targeted muscle (Borodic et al., 1994), that muscle fascia is an ineffective 
barrier for diffusion of the toxin (Shaari et al., 1991), and that doses of 10 U have 
biologic effects that spread across fascial planes to adjacent, noninjected muscles for 2.5 
– 4.5 cm from the injection site (Borodic et al., 1994; Borodic et al., 1990). However, 
muscles were not included in S-M layer. Therefore, even if BoNT diffuses to this layer, it 
may not have a direct effect.
In this study, we used snapshot to capture the video when using ultrasonography and 
measured thickness. Reference point was set on rest and then clenching motion was made. 
Thickness of maximal thick point of muscle and S-M was measured on maximum
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clenching state, than the thickness of same reference area was measured at rest. Ideally, 
same pressure should be loaded when measuring on maximum clenching and rest state. 
However, replacing the probe to acquire same pressure can cause change of measuring 
point from reference point. Also, maximum clenching time of a patient can only last few 
seconds making it technically impossible to replace the probe at the right time. Thus, the 
technique that has been used in this study can be considered clinically appropriate. 
Masseter muscle tends to push the probe away on clenching motion because of muscle 
contraction, which causes an increase in thickness and volume. Therefore, maintenance of 
an even pressure by a skilled researcher is crucial.
In this study, average of S-M thickness of total 17 people before BoNT injection was 
5.63mm at rest and 4.80mm at maximum clenching, showing a decrease at maximum 
clenching compared to rest state. This may be due to pressure of masseter muscle on 
subcutaneous tissue during contraction or stretching of subcutaneous tissue during 
clenching. We could not find a statistic significance in relationship of change in masseter 
muscle thickness and S-M thickness due to small number of experimental group, but this 
would be worth being studied in further experimentations.
The possibility of S-M thickness becoming thinner by pressure from thickened muscle 
during muscle contraction cannot be excluded. To measure this precisely, CT or MRI, 
which causes no pressure on the probe during clenching, would be the best choice to 
minimize measurement errors. However, maintaining consistent maximum clenching 
state during CT or MRI taking seems to be clinically hard to perform. This should be 
taken into consideration in following studies.
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Suh et al. reported that depth of masseter muscle from the skin surface using CT is 6.15
± 2.90mm in male and 7.37 ± 1.93mm in female, making female measurements larger 
than male, statistically significant (Suh et al., 2011). This seems to be related with 
difference in body fat of male and female. In our study, subcutaneous tissue thickness at 
rest before injection showed 5.63 mm in average, 8.04 mm in maximum. It is obvious that 
needle length should be over 8 mm when injecting BoNT into masseter muscle. Therefore, 
using 29-G ½-inch-long needle is recommended.
20
V. CONCLUSION
This study measured S-M and masseter thickness after BoNT injection and analyzed 
difference between experimental group and control group by time. As a result, masseter 
muscle thickness of experimental group decreased significantly by time, whereas S-M
thickness of experimental group and control group showed no significant difference. As 
a conclusion, BoNT is only effective on muscles and does not affect subcutaneous 
tissues around.
21
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ABSTRACT (in Korean)
교근부 보툴리눔 독소 주사 전후의
교근의 피부표면으로부터의 두께 변화
<지도 김 성 택 교수>
연세대학교 대학원 치의학과
박 건 우
보툴리눔독소 주사는 교근비대증의 치료를 위해 널리 사용되고 있다. 작용 기전은
보툴리눔독소가 신경의 말단에 작용하여 아세틸콜린의 분비를 억제함으로서 근육의
위축을 일으켜 치료효과를 나타낸다. 많은 연구에서 근육 두께의 변화에 대해
보고하였지만 피부 표면에서 교근까지 두께 변화에 대해서는 알려진 바가 없다. 본
연구에서는 초음파를 이용하여 근육의 두께 변화뿐만이 아니라 피부 표면에서
교근까지 두께 변화량을 측정하여 피하조직의 변화에 대해 관찰하고자 한다.
10명의 실험군과 7명의 대조군을 모집하여, 실험군에는 보툴리눔 독소를 양측
교근에 각각 25유닛씩 주사하였고 대조군은 식염수를 주사하였다. 주사 후 교근 및
피부 표면에서 교근까지 두께 변화량은 안정시와 최대 수축시에 주사 전, 4주 후, 8주
후, 12주 후에 측정하였다.
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실험 결과 피부 표면에서 교근까지 두께는 주사 후 안정시 (p = 0.063)와 최대
수축시 (p = 0.166) 시간의 변화에 따라 유의한 차이를 보이지 않았다. 실험군과
대조군 간에도 안정시 (p = 0.392)와 최대 수축시 (p = 0.259) 유의한 차이를
보이지 않았다. 실험군의 근육 두께량은 시간에 따라 유의한 차이를 보였다(p <
0.05). 따라서 보툴리눔독소 주사는 근육의 두께변화만을 일으키고 피부 표면에서
교근까지 두께변화에 영향을 미치지 않는다.
핵심되는 말: 보툴리눔 독소, 교근, 초음파
